Log in with your email address username.

×

[World Report] Biosimilars for insulin: a cost-saving alternative?

The expiry of patents on an insulin analogue has opened the market to the production of biosimilar insulins, but it is unclear if this will ultimately benefit patients. Chris McCall reports

email